|Articles|April 22, 2004

Aastrom Biosciences Inc. receives Phase I Small Business Innovation Research Grant (SBIR)

Aastrom Biosciences Inc. announced that it has received a Phase I Small Business Innovation Research Grant (SBIR) grant from the National Institutes of Health National Cancer Institute to develop an immunotherapeutic treatment of malignant melanoma using its AastromReplicell System cell production technology.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME